FDA Approved: NAGLAZYME — Supplemental Application (BioMarin Pharmaceutical Inc.)

View source ↗

Summary

FDA approved a supplemental application for NAGLAZYME (galsulfase) from BioMarin Pharmaceutical, expanding/adjusting its approved labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis Type Iva

Drugs mentioned

• NAGLAZYME (GALSULFASE)

Snippet

SUPPL AP for NAGLAZYME (GALSULFASE)